Study shows how human cells fight viral infections with the emergence of SARS-CoV-2
Reviewed by Emily Henderson, B.Sc.Sep 30 2020
Science's pursuits of unraveling how human cells fight viral infections kicked into high gear in 2020 with the devastating emergence of the SARS-CoV-2 virus.
A study published recently in eLife by University of California San Diego scientists describes fresh details about the mechanisms involved when individual human cells are attacked by viruses, with possible implications for COVID-19 clinical treatment.
The research helps advance science's understanding of interferons, a key group of immune response proteins released naturally by human cells when a virus is detected.
In response to a viral infection, human cells synthesize and secrete interferon-alpha, a chemical that triggers a series of biochemical reactions in cells, leading to the production of gene products that work to kill viruses or limit their spread. Interferon-alpha has been used clinically for more than 50 years in the treatments of diseases such as hepatitis B and C and HIV.
- Multifunctional cell therapy system raises hopes to treat inflammatory bowel disease
- Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2
- Research explains why flu is dangerous for pregnant women
However such efforts have been limited because interferon-alpha, in addition to inducing antiviral effects, also triggers cell refractoriness–or insensitivity–to further treatments. This stalled effectiveness takes hold within hours after drug administration and lasts for several days, resulting in a low therapeutic response rate.
Looking into the details of these processes, Biological Sciences PhD student Anusorn Mudla, Associate Professor Nan Hao and their colleagues used a combination of experimental analyses and mathematical modeling to describe the intricate time-dependent regulatory mechanisms that human cells use to control the duration and strength of antiviral responses triggered by interferon.
Their efforts resulted in the identification of a time delay in the production of USP18, an inhibitory factor that triggers cell refractoriness to prolonged interferon treatments.
Based on these findings, repetitive administrations of interferon to cells, with the duration shorter than the delay time, are less able to induce this inhibitory factor. This could potentially suggest strategies leading to a higher therapeutic response rate than the routine chronic treatment of the drug."
Hao, Researcher and Study Senior Author, Section of Molecular Biology,
The findings are especially relevant given the urgent need for new defense tactics against the SARS-CoV-2 virus and the global COVID-19 pandemic. The new findings shed light on possible ways to enhance the effectiveness of interferon for future clinical use.
"Recent studies have shown that SARS-CoV-2 is especially sensitive to interferon-alpha, compared to other coronaviruses, making interferon treatment a potential strategy to prevent SARS-CoV-2 infection," said Hao.
Based on this finding, researchers could now design time-dependent administrations of interferon in an effort to minimize the production of this inhibitory factor and boost therapeutic responses.